Checkpoint Therapeutics Inc

Wondering if you or a loved one should get screened for skin cancer following summer sun exposure? Skin cancer is the most common cancer in the U.S., and it can impact anyone, regardless of age or skin type. Evaluate your risk and learn more by visiting this blog and video from the Mayo Clinic: https://lnkd.in/g4KT63Ns cancer/#:~:text=Skin%20cancer%20is%20the%20most,people%20are%20at%20higher%20risk.

Think you know the signs of skin cancer? Early detection through a self-exam can make all the difference, so refresh your awareness and strengthen your ability to spot the symptoms by taking this interactive quiz from the Skin Cancer Foundation: https://lnkd.in/e597De-g. If you recognize any warning signs from the quiz, don’t hesitate to book an appointment with your dermatologist.

Did you know that you can help combat skin cancer from within? Though they don’t compare to other preventative measures like applying SPF and staying in the shade, antioxidants, such as berries, green vegetables, and other foods high in vitamins and nutrients, can actually help fight off harmful molecules that can form after UV exposure. For more information on foods and vitamins that doctors recommend to include in your skin cancer prevention routine, read this blog from the Skin Cancer Foundation: https://lnkd.in/g5EJDDhr

DIY skincare is trending, but homemade sunscreens may not provide adequate protection. Doctors warn these DIY formulas often fall short compared to professional SPF products. Checkpoint encourages you to learn more about effective sun protection and safe SPF alternatives from the Skin Cancer Foundation: https://lnkd.in/e4uam7n9

Checkpoint Therapeutics today announced that the U.S. Food and Drug Administration has accepted for review Checkpoint’s resubmission of its Biologics License Application for cosibelimab. The resubmission has been accepted as a complete response to the FDA’s December 2023 complete response letter and the FDA has set a Prescription Drug User Fee Act goal date of December 28, 2024. Read the full release: https://lnkd.in/g_aJ5-N4

Self-care looks different for everyone. On #InternationalSelfCareDay, Checkpoint Therapeutics encourages prioritizing personal care and sun protection. Consider implementing these tips in your daily routine: Avoid excessive sun exposure or bed tanning, as these activities can increase your risk of skin cancer. Always wear SPF skin protection when going outside for extended periods of time. Remember to treat your lips. Skin on the lips is sensitive and can be prone to sunburn if overexposed, so keep SPF lip balm with you. Check your skin regularly and contact your doctor with any concerns. For more information and additional resources, visit:  https://lnkd.in/e34uMm7

Today, Checkpoint Therapeutics and GC Cell announced a collaboration to explore the combined therapeutic potential of cosibelimab, Checkpoint’s anti-PD-L1 antibody with dual mechanism of action, with GC Cell’s Immuncell-LC, an innovative autologous Cytokine Induced Killer (CIK) T cell therapy composed of cytotoxic T lymphocytes and natural killer T cells. Read more about the partnership: https://lnkd.in/edDNAnMq

Checkpoint Therapeutics had the honor of attending the American Cancer Society's annual Red, White & Blue Party this year! This remarkable event gathers dedicated professionals and philanthropic leaders, all driven by a shared commitment to support the mission of the American Cancer Society. As a proud sponsor, Checkpoint believes in the power of community and the importance of giving back. We are immensely grateful to The American Cancer Society for their efforts in enhancing the lives of those affected by cancer.

Today, Checkpoint Therapeutics announced it has completed the resubmission of its Biologics License Application to the U.S. Food and Drug Administration for cosibelimab, its anti-programmed death ligand-1 (PD-L1) antibody, as a potential new treatment for patients with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or curative radiation. Read the full release: https://lnkd.in/eG5CY9nX

Today, Checkpoint Therapeutics announced it has reached alignment with the Food and Drug Administration on its biologics license application (BLA) resubmission strategy for cosibelimab. Accordingly, Checkpoint plans to move forward with a mid-year BLA resubmission seeking the U.S. marketing approval for cosibelimab as a potential new treatment for patients with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or curative radiation. Read the full release here: https://lnkd.in/eydHXwXx